An Old Drug, New Purpose: Amitriptyline for Asthma

Amitriptyline has been in clinical use since the early 1960s, and its appeal here has nothing to do with monoamines. The drug is a functional inhibitor of acid sphingomyelinase (ASM), the lysosomal enzyme that cleaves sphingomyelin into ceramide and thereby helps organize lipid rafts and caveolae.

Recently, researchers identified that ASM-knockout mice show reduced type 2 cytokine production and blunted airway hyperresponsiveness, suggesting ASM might be a therapeutic target in asthma. However, when amitriptyline was tested directly, its bronchodilatory effects persisted even in ASM-knockout mice, indicating the drug's airway-relaxing properties operate through mechanisms independent of ASM inhibition.

The precise mechanism remains unclear, though recent work suggests amitriptyline may disrupt lipid rafts and caveolae in airway smooth muscle cells. And so Michely and colleagues asked whether nebulized amitriptyline could address both acute bronchoconstriction and type 2 inflammation—two problems current therapy handles with separate drugs.

Study Design

The team layered four systems:

• A prophylactic ovalbumin (OVA) murine model, with nebulized amitriptyline (3.3 mg/mL) given daily for 35 days spanning sensitization and challenge.
• A therapeutic house dust mite (HDM) murine model, with amitriptyline started only after sensitization was already underway (day 7 through day 26).
• Ex vivo passively sensitized rat precision-cut lung slices (PCLS), a technique that keeps airway architecture and smooth muscle intact for direct contractility measurements.
• In vitro human Th2 lymphocytes differentiated from healthy donor blood, treated with 1 µM or 5 µM amitriptyline.

Lung mechanics were captured using FlexiVent forced oscillation technique, and inflammatory readouts included BALF eosinophils, T cells, IgE, and type 2 cytokines.

What the Data Show

The most compelling finding emerged consistently: inhaled amitriptyline improved lung mechanics in both models.

In the OVA model, total respiratory resistance (Rrs) decreased with a one-sided p-value of 0.007, while tissue elastance (H) also showed significant reduction (p=0.0103). Similar protective effects appeared in the HDM model, where one-sided t-tests revealed reductions in Rrs and elastance (Ers) (both p≤0.05), despite two-sided statistical tests missing significance.

The OVA model also showed that amitriptyline-treated mice had significantly reduced eosinophilic granulocytes and T cells in bronchoalveolar fluid compared to controls; however, IL-4 showed no significant change and IL-5 only trended lower without reaching statistical significance.

The HDM model revealed even more modest immunomodulatory effects. Neither inflammatory cell infiltration nor type 2 cytokines (IL-4 and IL-5) changed significantly. This divergence likely reflects the models' inherent differences: OVA induces classical type 2 inflammation with adjuvant, while HDM provokes more heterogeneous, clinically relevant responses. Lower serum amitriptyline levels in the HDM model (127.9 μg/L versus 220.4 μg/L in OVA) may also contribute to reduced immunological effects. Overall, amitriptyline's anti-inflammatory benefit appeared most pronounced through reduced inflammatory cell infiltration rather than direct cytokine suppression.

PCLS experiments demonstrated dose-dependent bronchodilation: 5 μM amitriptyline significantly attenuated ovalbumin-induced bronchoconstriction (p<0.001), while 1 μM showed no effect. This direct airway smooth muscle relaxation occurred independent of systemic immunity, suggesting a localized pharmacological action. Notably, inhaled administration avoided the weight gain associated with oral amitriptyline.

Lastly, human Th2 cells showed no significant changes in cytokine production or gene expression with amitriptyline treatment.

Reading Between the Lines

Taken together, the bronchodilatory effect looks robust and reproducible, while the immunomodulatory effect appears tied to timing, whether treatment starts before or after sensitization, and possibly to model choice. The authors are candid about this being exploratory, mechanistic work, and translational confirmation in more chronic, remodeling-relevant models is still needed.

Still, the combination of a direct, ASM-independent anti-obstructive effect with a context-dependent anti-inflammatory one is a genuinely intriguing profile, especially given the drug's already-known safety record and the absence of the weight gain that’s typically seen with oral dosing.

Reference: 
Michely A, Böll S, Yao L, et al. Effects of Inhaled Amitriptyline on Airway Function and Immune Responses in Experimental Asthma. Adv Respir Med. 2026;94(4):58. doi:10.3390/arm94040058